Literature DB >> 19615365

Attenuated neurotoxicity of the transactivation-defective HIV-1 Tat protein in hippocampal cell cultures.

Michael Y Aksenov1, Marina V Aksenova, Charles F Mactutus, Rosemarie M Booze.   

Abstract

This study reports that the cysteine 22-->glycine 22 substitution in the HIV-1 Tat 1-86 B significantly attenuates its neurotoxicity. Consistent with previous studies, direct interactions of rat hippocampal cells with Tat 1-86 B were shown to cause dose-dependent and time-dependent neurotoxicity associated with activation of caspases from the mitochondrial apoptotic pathway. Despite the similar binding/uptake properties, Cys22 Tat 1-86 B failed to induce significant neurotoxicity and activation of caspases 9 and 3/7 in hippocampal primary cultures. Results of the study underscore the important role of cysteine-rich domain in mechanism of Tat-mediated neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615365      PMCID: PMC2770879          DOI: 10.1016/j.expneurol.2009.07.005

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  33 in total

1.  Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon.

Authors:  A Nath; K Conant; P Chen; C Scott; E O Major
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

Review 2.  Decoding Tat: the biology of HIV Tat posttranslational modifications.

Authors:  Claudia Hetzer; Wilma Dormeyer; Martina Schnölzer; Melanie Ott
Journal:  Microbes Infect       Date:  2005-06-24       Impact factor: 2.700

Review 3.  HIV tat and neurotoxicity.

Authors:  J E King; E A Eugenin; C M Buckner; J W Berman
Journal:  Microbes Infect       Date:  2006-01-26       Impact factor: 2.700

Review 4.  Regulation of neural cell survival by HIV-1 infection.

Authors:  Gareth Jones; Christopher Power
Journal:  Neurobiol Dis       Date:  2005-11-17       Impact factor: 5.996

5.  HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy.

Authors:  Shaheen Shojania; Joe D O'Neil
Journal:  J Biol Chem       Date:  2006-01-19       Impact factor: 5.157

6.  Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor.

Authors:  Michael Y Aksenov; Marina V Aksenova; Avindra Nath; Philip D Ray; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2005-12-28       Impact factor: 4.294

7.  HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress.

Authors:  I I Kruman; A Nath; M P Mattson
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

Review 8.  Apoptosis and HIV infection: about molecules and genes.

Authors:  Andrea Cossarizza
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 9.  Neurobiology of HIV.

Authors:  Britta Hult; Gursharan Chana; Eliezer Masliah; Ian Everall
Journal:  Int Rev Psychiatry       Date:  2008-02

Review 10.  Molecular mechanisms of HIV-1 associated neurodegeneration.

Authors:  Hakan Ozdener
Journal:  J Biosci       Date:  2005-06       Impact factor: 2.795

View more
  17 in total

1.  Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.

Authors:  J-P Louboutin; L Agrawal; B A S Reyes; E J van Bockstaele; D S Strayer
Journal:  Neuroscience       Date:  2012-04-21       Impact factor: 3.590

Review 2.  Genetic variation and function of the HIV-1 Tat protein.

Authors:  Cassandra Spector; Anthony R Mele; Brian Wigdahl; Michael R Nonnemacher
Journal:  Med Microbiol Immunol       Date:  2019-03-05       Impact factor: 3.402

3.  HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures.

Authors:  M Y Aksenov; M V Aksenova; C F Mactutus; R M Booze
Journal:  Neurosci Lett       Date:  2010-04-02       Impact factor: 3.046

4.  Genetic attributes of blood-derived subtype-C HIV-1 tat and env in India and neurocognitive function.

Authors:  Myres W Tilghman; Jayanta Bhattacharya; Suprit Deshpande; Manisha Ghate; Stephen Espitia; Igor Grant; Thomas D Marcotte; Davey Smith; Sanjay Mehendale
Journal:  J Med Virol       Date:  2013-10-22       Impact factor: 2.327

5.  D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity.

Authors:  Michael Y Aksenov; M V Aksenova; C F Mactutus; Rosemarie M Booze
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-03       Impact factor: 4.147

6.  Neurodegenerative effects of recombinant HIV-1 Tat(1-86) are associated with inhibition of microtubule formation and oxidative stress-related reductions in microtubule-associated protein-2(a,b).

Authors:  Tracy R Butler; Katherine J Smith; Rachel L Self; Brittany B Braden; Mark A Prendergast
Journal:  Neurochem Res       Date:  2011-01-23       Impact factor: 3.996

7.  Dose-dependent neurocognitive deficits following postnatal day 10 HIV-1 viral protein exposure: Relationship to hippocampal anatomy parameters.

Authors:  Sylvia Fitting; Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2017-10-27       Impact factor: 2.457

8.  Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production.

Authors:  Xuesong Chen; Liang Hui; Nicholas H Geiger; Norman J Haughey; Jonathan D Geiger
Journal:  Neurobiol Aging       Date:  2013-05-11       Impact factor: 4.673

9.  Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens.

Authors:  Sarah J Bertrand; Charles F Mactutus; Marina V Aksenova; Tori D Espensen-Sturges; Rosemarie M Booze
Journal:  J Neurochem       Date:  2013-08-26       Impact factor: 5.372

10.  HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury.

Authors:  Sarah J Bertrand; Marina V Aksenova; Charles F Mactutus; Rosemarie M Booze
Journal:  Exp Neurol       Date:  2013-06-26       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.